FluoGuide gets green light to proceed to second dose level with FG001 in the ongoing clinical phase I/II trial in patients with high grade glioma

Copenhagen, Denmark, 17 December 2020 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the dose escalation committee has approved that administration of the second dose level can now be initiated in the ongoing trial evaluating safety and effcicacy of FG001 in patients with high grade glioma undergoing neurosurgery.

The release as fetched from its publisher. fluoguide.com ↗